New research looks at GLP-1's to treat gastrointestinal diseases
WJAR • • health
Key Points:
- Dr. Eric Newton, a gastroenterologist at University Gastroenterology, highlights that GLP-1 medications may reduce gut inflammation associated with diseases like Crohn's, colitis, and IBS, offering potential new treatment pathways beyond current options.
- GLP-1 drugs are also being studied for fatty liver disease, particularly in patients with advanced liver scarring but not cirrhosis, with hopes they can promote weight loss, reduce liver enzymes, and possibly reverse liver damage.
- University Gastroenterology is conducting three Eli Lilly-funded clinical trials: comparing Zepbound to biologic treatments for IBD, testing an experimental GLP-1 for IBS, and evaluating Zepbound and Retatrutide for fatty liver disease.
- Retatrutide is gaining attention due to its significant weight loss results in clinical trials, making it a promising option for fatty liver patients.
- Participation in these clinical trials offers patients free access to medications, comprehensive testing including blood work and imaging, and dedicated care from a specialized medical team.